Mycenax Biotech Inc.
4726.TWO
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.93B
Close$
Share Statistics
| Market cap | $4.93 Billion |
|---|---|
| Enterprise Value | $6.32 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.17 |
| Beta | 0.4 |
| Outstanding Shares | 207,136,000 |
Return
| Return on Equity | -27.12% |
|---|---|
| Return on Assets | -11.65% |
| Return on Invested Capital | -22.74% |
Valuation & Multiples
| P/E Ratio | -12.86 |
|---|---|
| PEG | 32.34 |
| Price to Sales | 7.93 |
| Price to Book Ratio | 3.97 |
| Enterprise Value to Revenue | 7.74 |
| Enterprise Value to EBIT | -15.03 |
| Enterprise Value to Net Income | -17 |
| Total Debt to Enterprise | 0.26 |
| Debt to Equity | 1.17 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.32
Average shareholder expectationRevenue Estimate
$214.00 M
Average shareholder expectationNext Earnings Call
Expected Date
November 18, 2026
EPS Estimate
$-0.28
Average shareholder expectationRevenue Estimate
$268.00 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Mycenax Biotech Inc.
387 employees
CEO: Pei-Jiun Chen Mycenax Biotech Inc. specializes in the research, development, and manufacturing of biopharmaceutical products, leveraging both mammalian and microbial cell culture systems. Its market reach extends across Taiwan, Europe, Asia, and the U...